146 filings
Page 2 of 8
NT 10-Q
yiewdm7is
14 Nov 22
Notice of late quarterly filing
4:53pm
8-K
nipeqn5ro0ou
19 Aug 22
Departure of Directors or Certain Officers
1:20pm
NT 10-Q
ms909
16 Aug 22
Notice of late quarterly filing
2:48pm
8-K
8mparlvs8dw2pvarfz0
28 Jul 22
CURE Pharmaceutical Announces the Sale of a Portion of its Platform Technology IP for $20 Million
9:51am
NT 10-K
gtn5fohuv 2k
31 Mar 22
Notice of late annual filing
7:52pm
8-K
iut gtl3afld50vqp2n7
7 Jan 22
Entry into a Material Definitive Agreement
4:30pm
8-K
o2l7bvbl07okfkg13
3 Dec 21
Departure of Directors or Certain Officers
4:01pm
8-K
cyrdzsdc zd
29 Apr 21
Entry into a Material Definitive Agreement
9:15am
8-K
a3ravjqlba mvzvuj8v
6 Apr 21
CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020
4:30pm
8-K
4qrkd qmep612
25 Feb 21
Entry into a Material Definitive Agreement
4:30pm
8-K
dh31m yfgdenfa8p
12 Feb 21
CURE Pharmaceutical Announces Promotions and Additions to Board of Directors
5:29pm
8-K
xvty5qtsw
6 Jan 21
CURE Pharmaceutical Receives FDA Approval for its IND Application
9:15am
8-K/A
8ndse8ur3
15 Dec 20
Financial Statements and Exhibits
9:15am